Skip to content
2000
Volume 22, Issue 5
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Diabetes mellitus (DM) is a growing global health concern, placing increasing strain on healthcare systems. Curcumin, the primary bioactive compound in (turmeric), has been reported to exhibit several therapeutic effects, including potential benefits for managing DM. However, its clinical use is limited by poor bioavailability. Nanotechnology, particularly nano-curcumin (nCUR), offers a promising solution by enhancing curcumin's delivery and effectiveness. Preclinical and clinical studies suggest that nCUR may help manage DM and its complications by reducing oxidative stress, genotoxicity, and mitochondrial dysfunction. Despite these promising results, the exact molecular mechanisms of nCUR remain unclear, and clinical evidence is still limited. Furthermore, there is a lack of global guidelines regulating the use of nanomaterials in medicine. In summary, while nCUR shows strong potential as a therapeutic option for diabetes, further research is necessary to elucidate its mechanisms, confirm its clinical efficacy and safety, and establish standardized guidelines for its use in healthcare.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998400703250729191528
2025-08-21
2026-04-17

  • From This Site

    /content/journals/cdr/10.2174/0115733998400703250729191528
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cdr/22/5/CDR-22-5-07.html?itemId=/content/journals/cdr/10.2174/0115733998400703250729191528&mimeType=html&fmt=ahah

References

  1. Al-LawatiJ.A. Diabetes mellitus: A local and global public health emergency.Oman Med. J.201732317717910.5001/omj.2017.3428584596
     [Google Scholar]
  2. SunH. SaeediP. KarurangaS. PinkepankM. OgurtsovaK. DuncanB.B. SteinC. BasitA. ChanJ.C.N. MbanyaJ.C. PavkovM.E. RamachandaranA. WildS.H. JamesS. HermanW.H. ZhangP. BommerC. KuoS. BoykoE.J. MaglianoD.J. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.Diabetes Res. Clin. Pract.202218310911910.1016/j.diabres.2021.10911934879977
     [Google Scholar]
  3. OjoO. KalocsányiováE. McCroneP. ElliottH. MilliganW. GkaintatziE. Non-Pharmacological interventions for type 2 diabetes in people living with severe mental illness: Results of a systematic review and meta-analysis.Int. J. Environ. Res. Public Health202421442310.3390/ijerph2104042338673334
     [Google Scholar]
  4. ChaiyasutC. WoraharnS. SivamaruthiB.S. LailerdN. KesikaP. PeerajanS. Lactobacillus fermentum HP3 mediated fermented Hericium erinaceus juice as a health promoting food supplement to manage diabetes mellitus.J. Evid. Based Integr. Med.2018232515690X1876569910.1177/2515690X1876569929619846
     [Google Scholar]
  5. SivamaruthiB.S. KesikaP. PrasanthM.I. ChaiyasutC. A mini review on antidiabetic properties of fermented foods.Nutrients20181012197310.3390/nu1012197330551623
     [Google Scholar]
  6. SivamaruthiB. KesikaP. ChaiyasutC. A comprehensive review on anti-diabetic property of rice bran.Asian Pac. J. Trop. Biomed.201881798410.4103/2221‑1691.221142
     [Google Scholar]
  7. ChaiyasutC. SivamaruthiB.S. KesikaP. SubasankariK. Beneficial effects of anthocyanins against diabetes mellitus associated consequences-A mini review.Asian Pac. J. Trop. Biomed.201881047147710.4103/2221‑1691.244137
     [Google Scholar]
  8. YedjouC.G. GrigsbyJ. MbemiA. NelsonD. MildortB. LatinwoL. TchounwouP.B. The management of diabetes mellitus using medicinal plants and vitamins.Int. J. Mol. Sci.20232410908510.3390/ijms2410908537240430
     [Google Scholar]
  9. Otto-BuczkowskaE. JaintaN. Pharmacological treatment in diabetes mellitus Type 1 – Insulin and what else?Int. J. Endocrinol. Metab.2017161e1300810.5812/ijem.1300829696037
     [Google Scholar]
  10. Weinberg SibonyR. SegevO. DorS. RazI. Drug therapies for diabetes.Int. J. Mol. Sci.202324241714710.3390/ijms24241714738138975
     [Google Scholar]
  11. AnsariP. KhanJ.T. ChowdhuryS. ReberioA.D. KumarS. SeidelV. Abdel-WahabY.H.A. FlattP.R. Plant-based diets and phytochemicals in the management of diabetes mellitus and prevention of its complications: A review.Nutrients20241621370910.3390/nu1621370939519546
     [Google Scholar]
  12. KongM. XieK. LvM. LiJ. YaoJ. YanK. WuX. XuY. YeD. Anti-inflammatory phytochemicals for the treatment of diabetes and its complications: Lessons learned and future promise.Biomed. Pharmacother.202113311097510.1016/j.biopha.2020.11097533212375
     [Google Scholar]
  13. BacanliM. DilsizS.A. BaşaranN. BaşaranA.A. Effects of phytochemicals against diabetes.Adv. Food Nutr. Res.20198920923810.1016/bs.afnr.2019.02.00631351526
     [Google Scholar]
  14. TaylorS.I. YazdiZ.S. BeitelsheesA.L. Pharmacological treatment of hyperglycemia in type 2 diabetes.J. Clin. Invest.20211312e14224310.1172/JCI14224333463546
     [Google Scholar]
  15. VaughanE.M. Santiago-DelgadoZ.M. Management of type 2 diabetes mellitus with noninsulin pharmacotherapy.Am. Fam. Physician2024109433334238648832
     [Google Scholar]
  16. NgK.W. AllenM.L. DesaiA. MacraeD. PathanN. Cardioprotective effects of insulin: How intensive insulin therapy may benefit cardiac surgery patients.Circulation2012125572172810.1161/CIRCULATIONAHA.111.06378422311884
     [Google Scholar]
  17. Galdón Sanz-PastorA. Justel EnríquezA. Sánchez BaoA. Ampudia-BlascoF.J. Current barriers to initiating insulin therapy in individuals with type 2 diabetes.Front. Endocrinol. (Lausanne)202415136636810.3389/fendo.2024.136636838559691
     [Google Scholar]
  18. IwealaE.J. UcheM.E. DikeE.D. EtumnuL.R. DokunmuT.M. OluwapelumiA.E. OkoroB.C. DaniaO.E. AdebayoA.H. UgboguE.A. Curcuma longa (Turmeric): Ethnomedicinal uses, phytochemistry, pharmacological activities and toxicity profiles—A review.Pharmacol. Res. Mod. Chin. Med.2023610022210.1016/j.prmcm.2023.100222
     [Google Scholar]
  19. ChenJ. XiaN. ZhaoJ. ChenJ. HennyR.J. Chromosome numbers and ploidy levels of Chinese Curcuma species.HortScience201348552553010.21273/HORTSCI.48.5.525
     [Google Scholar]
  20. PoudelA. PandeyJ. LeeH.K. Geographical discrimination in curcuminoids content of turmeric assessed by rapid UPLC-DAD validated analytical method.Molecules2019249180510.3390/molecules2409180531083285
     [Google Scholar]
  21. HabsahM. AmranM. MackeenM.M. LajisN.H. KikuzakiH. NakataniN. RahmanA.A. Ghafar AliA.M. Screening of Zingiberaceae extracts for antimicrobial and antioxidant activities.J. Ethnopharmacol.200072340341010.1016/S0378‑8741(00)00223‑310996279
     [Google Scholar]
  22. AgarwalN.B. JainS. NagpalD. AgarwalN.K. MedirattaP.K. SharmaK.K. Liposomal formulation of curcumin attenuates seizures in different experimental models of epilepsy in mice.Fundam. Clin. Pharmacol.201327216917210.1111/j.1472‑8206.2011.01002.x22044441
     [Google Scholar]
  23. GuptaS.C. PatchvaS. AggarwalB.B. Therapeutic roles of curcumin: Lessons learned from clinical trials.AAPS J.201315119521810.1208/s12248‑012‑9432‑823143785
     [Google Scholar]
  24. MirzaeiH. KhoiM.J.M. AziziM. GoodarziM. Can curcumin and its analogs be a new treatment option in cancer therapy?Cancer Gene Ther.2016231141010.1038/cgt.2016.4727853147
     [Google Scholar]
  25. NelsonK.M. DahlinJ.L. BissonJ. GrahamJ. PauliG.F. WaltersM.A. The essential medicinal chemistry of curcumin.J. Med. Chem.20176051620163710.1021/acs.jmedchem.6b0097528074653
     [Google Scholar]
  26. PrasadS. GuptaS.C. TyagiA.K. AggarwalB.B. Curcumin, a component of golden spice: From bedside to bench and back.Biotechnol. Adv.20143261053106410.1016/j.biotechadv.2014.04.00424793420
     [Google Scholar]
  27. AggarwalB.B. KumarA. BhartiA.C. Anticancer potential of curcumin: Preclinical and clinical studies.Anticancer Res.2003231A36339812680238
     [Google Scholar]
  28. FanZ. YaoJ. LiY. HuX. ShaoH. TianX. Anti-inflammatory and antioxidant effects of curcumin on acute lung injury in a rodent model of intestinal ischemia reperfusion by inhibiting the pathway of NF-Kb.Int. J. Clin. Exp. Pathol.2015843451345926097529
     [Google Scholar]
  29. Abbas MomtaziA. SahebkarA. Difluorinated curcumin: A promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile.Curr. Pharm. Des.201622284386439710.2174/138161282266616052711350127229723
     [Google Scholar]
  30. RahmaniS. AsgaryS. AskariG. KeshvariM. HatamipourM. FeiziA. SahebkarA. Treatment of non-alcoholic fatty liver disease with curcumin: A randomized placebo-controlled trial.Phytother. Res.20163091540154810.1002/ptr.565927270872
     [Google Scholar]
  31. HewlingsS. KalmanD. Curcumin: A review of its effects on human health.Foods20176109210.3390/foods610009229065496
     [Google Scholar]
  32. MirzaeiH. ShakeriA. RashidiB. JaliliA. BanikazemiZ. SahebkarA. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies.Biomed. Pharmacother.20178510211210.1016/j.biopha.2016.11.09827930973
     [Google Scholar]
  33. ZhuJ.Y. YangX. ChenY. JiangY. WangS.J. LiY. WangX.Q. MengY. ZhuM.M. MaX. HuangC. WuR. XieC.F. LiX.T. GengS.S. WuJ.S. ZhongC.Y. HanH.Y. Curcumin suppresses lung cancer stem cells via inhibiting Wnt/β-catenin and sonic hedgehog pathways.Phytother. Res.201731468068810.1002/ptr.579128198062
     [Google Scholar]
  34. PanahiY. KhaliliN. SahebiE. NamaziS. ReinerŽ. MajeedM. SahebkarA. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial.Complement. Ther. Med.2017331510.1016/j.ctim.2017.05.00628735818
     [Google Scholar]
  35. Momtazi-BorojeniA.A. HaftcheshmehS.M. EsmaeiliS.A. JohnstonT.P. AbdollahiE. SahebkarA. Curcumin: A natural modulator of immune cells in systemic lupus erythematosus.Autoimmun. Rev.201817212513510.1016/j.autrev.2017.11.01629180127
     [Google Scholar]
  36. ParsamaneshN. MoossaviM. BahramiA. ButlerA.E. SahebkarA. Therapeutic potential of curcumin in diabetic complications.Pharmacol. Res.201813618119310.1016/j.phrs.2018.09.01230219581
     [Google Scholar]
  37. BavarsadK. BarretoG.E. HadjzadehM.A.R. SahebkarA. Protective effects of curcumin against ischemia-reperfusion injury in the nervous system.Mol. Neurobiol.20195621391140410.1007/s12035‑018‑1169‑729948942
     [Google Scholar]
  38. GhasemiF. BagheriH. BarretoG.E. ReadM.I. SahebkarA. Effects of curcumin on microglial cells.Neurotox. Res.2019361122610.1007/s12640‑019‑00030‑030949950
     [Google Scholar]
  39. HasanzadehS. ReadM.I. BlandA.R. MajeedM. JamialahmadiT. SahebkarA. Curcumin: An inflammasome silencer.Pharmacol. Res.202015910492110.1016/j.phrs.2020.10492132464325
     [Google Scholar]
  40. Vahedian-AzimiA. AbbasifardM. Rahimi-BasharF. GuestP.C. MajeedM. MohammadiA. BanachM. JamialahmadiT. SahebkarA. Effectiveness of curcumin on outcomes of hospitalized COVID-19 patients: A systematic review of clinical trials.Nutrients202214225610.3390/nu1402025635057437
     [Google Scholar]
  41. HamzaE.K. JaafarS.N. Nanotechnology application for wireless communication system.Nanotechnology for Electronic Applications. Materials Horizons: From Nature to Nanomaterials. MubarakN.M. GopiS. BalakrishnanP. SingaporeSpringer202211513010.1007/978‑981‑16‑6022‑1_6
     [Google Scholar]
  42. PayalP.P. PandeyP. Role of nanotechnology in electronics: A review of recent developments and patents.Recent Pat. Nanotechnol.2022161456610.2174/187221051566621012011450433494686
     [Google Scholar]
  43. IbrahimR.K. HayyanM. AlSaadiM.A. HayyanA. IbrahimS. Environmental application of nanotechnology: Air, soil, and water.Environ. Sci. Pollut. Res. Int.20162314137541378810.1007/s11356‑016‑6457‑z27074929
     [Google Scholar]
  44. FracetoL.F. GrilloR. de MedeirosG.A. ScognamiglioV. ReaG. BartolucciC. Nanotechnology in agriculture: Which innovation potential does it have?Front. Environ. Sci.201642010.3389/fenvs.2016.00020
     [Google Scholar]
  45. NemeK. NafadyA. UddinS. TolaY.B. Application of nanotechnology in agriculture, postharvest loss reduction and food processing: Food security implication and challenges.Heliyon2021712e0853910.1016/j.heliyon.2021.e0853934934845
     [Google Scholar]
  46. NileS.H. BaskarV. SelvarajD. NileA. XiaoJ. KaiG. Nanotechnologies in food science: Applications, recent trends, and future perspectives.Nano-Micro Lett.20201214510.1007/s40820‑020‑0383‑934138283
     [Google Scholar]
  47. SivamaruthiB.S. RamkumarV.S. ArchunanG. ChaiyasutC. SuganthyN. Biogenic synthesis of silver palladium bimetallic nanoparticles from fruit extract of Terminalia chebula – In vitro evaluation of anticancer and antimicrobial activity.J. Drug Deliv. Sci. Technol.20195113915110.1016/j.jddst.2019.02.024
     [Google Scholar]
  48. PrakashkumarN. SivamaruthiB.S. ChaiyasutC. SuganthyN. Decoding the neuroprotective potential of methyl gallate-loaded starch nanoparticles against beta amyloid-induced oxidative stress-mediated apoptosis: An in vitro study.Pharmaceutics202113329910.3390/pharmaceutics1303029933668877
     [Google Scholar]
  49. SivamaruthiB. ThangaleelaS. KesikaP. SuganthyN. ChaiyasutC. Mesoporous silica-based nanoplatforms are theranostic agents for the treatment of inflammatory disorders.Pharmaceutics202315243910.3390/pharmaceutics1502043936839761
     [Google Scholar]
  50. SivamaruthiB.S. KapoorD.U. KukkarR.R. GaurM. ElossailyG.M. PrajapatiB.G. ChaiyasutC. Mesoporous silica nanoparticles: Types, synthesis, role in the treatment of Alzheimer’s disease, and other applications.Pharmaceutics20231512266610.3390/pharmaceutics1512266638140007
     [Google Scholar]
  51. ChaiyasutC. SivamaruthiB.S. JungsinyatamP. TansrisookC. JinaratD. ChaiyasutK. PeerajanS. RungseevijitprapaW. Development and evaluation of Elaeagnus rhamnoides (L.) A. Nelson oil-loaded nanostructured lipid carrier for improved skin hydration.Appl. Sci.20221216832410.3390/app12168324
     [Google Scholar]
  52. SisubalanN. ShaliniR. RamyaS. SivamaruthiB.S. ChaiyasutC. Recent advances in nanomaterials for neural applications: Opportunities and challenges.Nanomedicine (Lond.)202318261979199410.2217/nnm‑2023‑026138078433
     [Google Scholar]
  53. KhosropanahM.H. DinarvandA. NezhadhosseiniA. HaghighiA. HashemiS. NirouzadF. KhatamsazS. EntezariM. HashemiM. DehghaniH. Analysis of the antiproliferative effects of curcumin and nanocurcumin in MDA-MB231 as a breast cancer cell line.Iran. J. Pharm. Res.201615123123927610163
     [Google Scholar]
  54. DendeC. MeenaJ. NagarajanP. NagarajV.A. PandaA.K. PadmanabanG. Nanocurcumin is superior to native curcumin in preventing degenerative changes in experimental cerebral malaria.Sci. Rep.2017711006210.1038/s41598‑017‑10672‑928855623
     [Google Scholar]
  55. LiuQ. JingY. HanC. ZhangH. TianY. Encapsulation of curcumin in zein/caseinate/sodium alginate nanoparticles with improved physicochemical and controlled release properties.Food Hydrocoll.20199343244210.1016/j.foodhyd.2019.02.003
     [Google Scholar]
  56. Shamsi-GoushkiA. MortazaviZ. MirshekarM.A. MohammadiM. Moradi-KorN. Jafari-MaskouniS. ShahrakiM. Comparative effects of curcumin versus nano-curcumin on insulin resistance, serum levels of apelin and lipid profile in type 2 diabetic rats.Diabetes Metab. Syndr. Obes.2020132337234610.2147/DMSO.S24735132753918
     [Google Scholar]
  57. LuW Khatibi ShahidiF KhorsandiK HosseinzadehR GulA BalickV. An update on molecular mechanisms of curcumin effect on diabetes. J Food Biochem20224610e1435810.1111/jfbc.14358
     [Google Scholar]
  58. KarthikeyanA. SenthilN. MinT. Nanocurcumin: A promising candidate for therapeutic applications.Front. Pharmacol.20201148710.3389/fphar.2020.0048732425772
     [Google Scholar]
  59. ChenY. LuY. LeeR.J. XiangG. Nano encapsulated Curcumin: And its potential for biomedical applications.Int. J. Nanomedicine2020153099312010.2147/IJN.S21032032431504
     [Google Scholar]
  60. RahimiH.R. MohammadpourA.H. DastaniM. JaafariM.R. AbnousK. Ghayour MobarhanM. Kazemi OskueeR. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial.Avicenna J. Phytomed.20166556757727761427
     [Google Scholar]
  61. HamedA.M. ElbahyD.A. AhmedA.R.H. ThabetS.A. RefaeiR.A. RagabI. ElmahdyS.M. OsmanA.S. AbouelellaA.M.A. Comparison of the efficacy of curcumin and its nano formulation on dexamethasone-induced hepatic steatosis, dyslipidemia, and hyperglycemia in Wistar rats.Heliyon20241024e4104310.1016/j.heliyon.2024.e4104339759349
     [Google Scholar]
  62. FoulkesR. ManE. ThindJ. YeungS. JoyA. HoskinsC. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives.Biomater. Sci.20208174653466410.1039/D0BM00558D32672255
     [Google Scholar]
  63. SoaresS. SousaJ. PaisA. VitorinoC. Nanomedicine: Principles, properties, and regulatory issues.Front Chem.2018636010.3389/fchem.2018.0036030177965
     [Google Scholar]
  64. Halamoda-KenzaouiB. GeertsmaR. PouwJ. Prina-MelloA. CarrerM. RoessleinM. SipsA. WeltringK.M. SpringK. Bremer-HoffmannS. Future perspectives for advancing regulatory science of nanotechnology-enabled health products.Drug Deliv. Transl. Res.20221292145215610.1007/s13346‑022‑01165‑y35691982
     [Google Scholar]
  65. GebelT. FothH. DammG. FreybergerA. KramerP.J. LilienblumW. RöhlC. SchuppT. WeissC. WollinK.M. HengstlerJ.G. Manufactured nanomaterials: Categorization and approaches to hazard assessment.Arch. Toxicol.201488122191221110.1007/s00204‑014‑1383‑725326817
     [Google Scholar]
  66. IlinskayaA.N. DobrovolskaiaM.A. Nanoparticles and the blood coagulation system. Part II: Safety concerns.Nanomedicine (Lond.)20138696998110.2217/nnm.13.4923730696
     [Google Scholar]
  67. Chibuike Daraojimba DaraojimbaC. OfonagoroK.A. Economic impacts and innovations in materials science: a holistic exploration of nanotechnology and advanced materials.Eng. Sci. Technol. J.2023438410010.51594/estj.v4i3.553
     [Google Scholar]
  68. Drug Products, Including Biological Products that Contain Nanomaterials, Guidance for Industry.2022Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry
  69. Oualikene-GoninW. SautouV. EzanE. BastosH. BellissantE. BelgodèreL. MaisonP. AnkriJ. Scientific Advisory Board of the ANSM Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines and Health Products.Front. Public Health202311112557710.3389/fpubh.2023.112557736935690
     [Google Scholar]
  70. YallapuM.M. NageshP.K.B. JaggiM. ChauhanS.C. Therapeutic applications of curcumin nanoformulations.AAPS J.20151761341135610.1208/s12248‑015‑9811‑z26335307
     [Google Scholar]
  71. ChenX. ZouL.Q. NiuJ. LiuW. PengS.F. LiuC.M. The stability, sustained release and cellular antioxidant activity of curcumin nanoliposomes.Molecules2015208142931431110.3390/molecules20081429326251892
     [Google Scholar]
  72. HatamipourM. SahebkarA. AlavizadehS.H. DorriM. JaafariM.R. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids.Iran. J. Basic Med. Sci.201922328228910.22038/ijbms.2019.32873.785231156789
     [Google Scholar]
  73. LiZ. ShiM. LiN. XuR. Application of functional biocompatible nanomaterials to improve curcumin bioavailability.Front Chem.2020858995710.3389/fchem.2020.58995733134284
     [Google Scholar]
  74. PrasadS. TyagiA.K. AggarwalB.B. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: The golden pigment from golden spice.Cancer Res. Treat.201446121810.4143/crt.2014.46.1.224520218
     [Google Scholar]
  75. TomehM.A. HadianamreiR. ZhaoX. A review of curcumin and its derivatives as anticancer agents.Int. J. Mol. Sci.2019205103310.3390/ijms2005103330818786
     [Google Scholar]
  76. SachdevaA. DhawanD. JainG.K. YererM.B. CollignonT.E. TewariD. BishayeeA. Novel strategies for the bioavailability augmentation and efficacy improvement of natural products in oral cancer.Cancers202215126810.3390/cancers1501026836612264
     [Google Scholar]
  77. GanugulaR. AroraM. JaisamutP. WiwattanapatapeeR. JørgensenH.G. VenkatpurwarV.P. ZhouB. Rodrigues HoffmannA. BasuR. GuoS. MajetiN.V.R.K. Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus.Br. J. Pharmacol.2017174132074208410.1111/bph.1381628409821
     [Google Scholar]
  78. JiaT. RaoJ. ZouL. ZhaoS. YiZ. WuB. LiL. YuanH. ShiL. ZhangC. GaoY. LiuS. XuH. LiuH. LiangS. LiG. Nanoparticle-encapsulated curcumin inhibits diabetic neuropathic pain involving the P2Y12 receptor in the dorsal Root Ganglia.Front. Neurosci.20181175510.3389/fnins.2017.0075529422835
     [Google Scholar]
  79. Abdel-MageidA.D. Abou-SalemM.E.S. SalaamN.M.H.A. El-GarhyH.A.S. The potential effect of garlic extract and curcumin nanoparticles against complication accompanied with experimentally induced diabetes in rats.Phytomedicine20184312613410.1016/j.phymed.2018.04.03929747745
     [Google Scholar]
  80. El-NaggarM.E. Al-JoufiF. AnwarM. AttiaM.F. El-BanaM.A. Curcumin-loaded PLA-PEG copolymer nanoparticles for treatment of liver inflammation in streptozotocin-induced diabetic rats.Colloids Surf. B Biointerfaces201917738939810.1016/j.colsurfb.2019.02.02430785036
     [Google Scholar]
  81. DadgarH. KermanshahiH. JaafariM.R. JavadmaneshA. Effects of curcumin and its nano-micelle formulation on body weight, insulin resistance, adiponectin, and blood biochemical parameters of streptozotocin-induced diabetic rats.Iran. J. Vet. Sci. Technol.20221433845
     [Google Scholar]
  82. MetaweaM.R. AbdelrazekH.M.A. El-HakH.N.G. MoghazeeM.M. MarieO.M. Comparative effects of curcumin versus nano-curcumin on histological, immunohistochemical expression, histomorphometric, and biochemical changes to pancreatic beta cells and lipid profile of streptozocin induced diabetes in male Sprague–Dawley rats.Environ. Sci. Pollut. Res. Int.20233022620676207910.1007/s11356‑023‑26260‑636932309
     [Google Scholar]
  83. Shamsi-GoushkiA. MortazaviZ. BehrasiF. EbrahimkhaniA. HosseiniR. Effects of Curcumin and Nanocurcumin supplementation on serum brain-derived neurotrophic factor and some complications in type 2 diabetic rats.Nanomed. J.2023102122130
     [Google Scholar]
  84. RahamanS.M. DuttaG. BiswasR. SugumaranA. SalemM.M. GamalM. AbdElrahmanM. Salem-BekhitM.M. Succinyl curcumin conjugated chitosan polymer-prodrug nanomicelles: A potential treatment for type-II diabetes in diabetic Balb/C Mice.Acta Chim. Slov.202471242143510.17344/acsi.2024.865838919100
     [Google Scholar]
  85. GanugulaR. NuthalapatiN.K. DwivediS. ZouD. AroraM. FriendR. Sheikh-HamadD. BasuR. KumarM.N.V.R. Nanocurcumin combined with insulin alleviates diabetic kidney disease through P38/P53 signaling axis.J. Control. Release202335362163310.1016/j.jconrel.2022.12.01236503070
     [Google Scholar]
  86. FerradjS. YahoumM.M. RebihaM. NabiI. ToumiS. LefnaouiS. Hadj-Ziane-ZafourA. TouzoutN. TahraouiH. MihoubA. SeleimanM.F. AliN. ZhangJ. AmraneA. Nanocurcumin-based sugar-free formulation: Development and impact on diabetes and oxidative stress reduction.Nanomaterials20241413110510.3390/nano1413110538998710
     [Google Scholar]
  87. DeyS. SowP. DeyR. GuptaroyP. NandiS. SamadderA. Design, synthesis and therapeutic exploration of nano-curcumin targeting the synergistic interactions with p53 and PARP-1 proteins in preventing food-additive induced genotoxicity and diabetic complications.Colloids Surf. A Physicochem. Eng. Asp.202571013623010.1016/j.colsurfa.2025.136230
     [Google Scholar]
  88. AlharthiN.S. Fabrication of curcumin‑incorporated poly glycerol sebacate/poly lactide acid (PGS/PLA) hydrogel to enhance full‑thickness wound healing in diabetic rats.Tissue Cell20259510285610.1016/j.tice.2025.10285640120429
     [Google Scholar]
  89. AsadiS. GholamiM.S. SiassiF. QorbaniM. KhamoshianK. SotoudehG. Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus: A randomized double-blind placebo- controlled clinical trial.Complement. Ther. Med.20194325326010.1016/j.ctim.2019.02.01430935539
     [Google Scholar]
  90. AsadiS. GholamiM.S. SiassiF. QorbaniM. SotoudehG. Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial.Phytother. Res.202034489690310.1002/ptr.657131788880
     [Google Scholar]
  91. ShafabakhshR. AsemiZ. ReinerZ. SoleimaniA. AghadavodE. BahmaniF. The effects of nano-curcumin on metabolic status in patients with diabetes on hemodialysis, a randomized, double blind, placebo-controlled trial.Iran. J. Kidney Dis.202014429029932655024
     [Google Scholar]
  92. DastaniM. RahimiH.R. AskariV.R. JaafariM.R. JarahiL. YadollahiA. RahimiV.B. Three months of combination therapy with nano-curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double-blinded, placebo-controlled clinical trial.Biofactors202349110811810.1002/biof.187435674733
     [Google Scholar]
  93. AsghariK.M. SalehP. SalekzamaniY. DolatkhahN. AghamohammadzadehN. HashemianM. The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: A double-blinded randomized clinical trial.Nutr. Diabetes20241411410.1038/s41387‑024‑00274‑638589346
     [Google Scholar]
  94. GeerlingsS.E. Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment.Int. J. Antimicrob. Agents200831Suppl. 1545710.1016/j.ijantimicag.2007.07.04218054467
     [Google Scholar]
  95. MullerL.M.A.J. GorterK.J. HakE. GoudzwaardW.L. SchellevisF.G. HoepelmanA.I.M. RuttenG.E.H.M. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.Clin. Infect. Dis.200541328128810.1086/43158716007521
     [Google Scholar]
  96. BerbudiA. RahmadikaN. TjahjadiA.I. RuslamiR. Type 2 diabetes and its impact on the immune system.Curr. Diabetes Rev.202016544244910.2174/18756417MTAxgODQqy31657690
     [Google Scholar]
  97. DonathM.Y. ShoelsonS.E. Type 2 diabetes as an inflammatory disease.Nat. Rev. Immunol.20111129810710.1038/nri292521233852
     [Google Scholar]
  98. EguchiN. VaziriN.D. DafoeD.C. IchiiH. The role of oxidative stress in pancreatic β cell dysfunction in diabetes.Int. J. Mol. Sci.2021224150910.3390/ijms2204150933546200
     [Google Scholar]
  99. NitaM. GrzybowskiA. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults.Oxid. Med. Cell. Longev.201620161316473410.1155/2016/316473426881021
     [Google Scholar]
  100. TangvarasittichaiS. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus.World J. Diabetes20156345648010.4239/wjd.v6.i3.45625897356
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998400703250729191528
Loading
Nano-curcumin for the Treatment and Management of Diabetes Mellitus
Curr. Diabetes Rev. 22, E15733998400703 (2026); https://doi.org/10.2174/0115733998400703250729191528
/content/journals/cdr/10.2174/0115733998400703250729191528
/content/journals/cdr/10.2174/0115733998400703250729191528
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Bioactivity; curcuma longa l; curcumin; diabetes mellitus; molecular players; nanomedicine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test